Neuroscience 2002 Abstract
| Presentation Number: | 196.15 |
|---|---|
| Abstract Title: | Potential neuroprotective characteristics of endogenous cannabinoids on excitotoxic neurodegeneration in the <i>spastic</i>Han-Wistar rat. |
| Authors: |
Iniquez, J. A.*1
; Ochoa, A. E.1
; Toledo, D.1
; Frimerman, A.1
; Villasenor, P.1
; Cohen, R. W.1
1California State University, Northridge, CA |
| Primary Theme and Topics |
Neurological and Psychiatric Conditions - Neurodegenerative Disorders -- Other |
| Secondary Theme and Topics | Neurological and Psychiatric Conditions<br />- Neurotoxicity<br />-- Toxic metabolic effects and disorders |
| Session: |
196. Neural degeneration: stem cells, gene therapy and neural profection Poster |
| Presentation Time: | Sunday, November 3, 2002 3:00 PM-4:00 PM |
| Location: | Hall A2-B3 X-27 |
| Keywords: | cerebellum, hippocampus, anandamide, CB1 receptors |
Many studies have shown that the active components of marijuana (cannabinoids) demonstrate neuroprotective properties in animal models of ischemia, PD and HD. Both exogenous and endogenous cannabinoids bind to CB1 receptors found in several areas of the brain, including the cerebellum and hippocampus. Our lab studies the spasticHan-Wistar rat (sHW), a genetic model of glutamate excitotoxicity, that exhibits neurodegeneration in the cerebellum and hippocampus, beginning at 30 days of age. This progressive disorder generates hyperactivity, fore limb tremor, and hind limb ataxia, leading to death due to respiratory difficulties. This current study was conducted to investigate the potential neuroprotective properties of cannabinoids on the sHW rat. An equal mix of mutant and normal siblings was used in this study. At 24-28 days of age, the animals were treated with either one of two agonists, 0.1 mg/kg anandamide (n=15) and 0.1 mg/kg R-(+)-Win 55,212-2 (n=10), the cannabinoid antagonist SR141716A (n=11) or vehicle (DMSO; n=35). The injections were administered IP twice a week on nonconsecutive days for three weeks. Quantification of motor activities included ambulation (number of squares entered) and rearing (number of times the rat stood on its hind legs). While R-(+)-Win 55,212-2 showed a slight (3%) increase in motor activity and longevity, anandamide had no effect when compared to the vehicle controls. The antagonist SR141716A decreased longevity by 6%. These results indicate that cannabinoid agonist R-(+)-Win 55,212-2 may serve as a neuroprotective agent in neurodegenerative diseases.
Supported by NIDA, NIH MARC and RISE/MBRS.
Sample Citation:
[Authors]. [Abstract Title]. Program No. XXX.XX. 2002 Neuroscience Meeting Planner. Orlando, FL: Society for Neuroscience, 2002. Online.
Copyright © 2002-2025 Society for Neuroscience; all rights reserved. Permission to republish any abstract or part of any abstract in any form must be obtained in writing by SfN office prior to publication.
